Deliver Your News to the World

Edity Therapeutics Announces Appointment of Abigail Bracha, PhD as President

Rehovot, Israel – WEBWIRE
Edity’s New President, Abigail Bracha, PhD
Edity’s New President, Abigail Bracha, PhD

Edity Therapeutics, a first-in-category cellular delivery company, announced today that Abigail Bracha, PhD, has joined as President.

As Edity’s President, Abigail will play a critical role in enabling the company to bring its breakthrough innovations in cellular delivery to patients with severe diseases. Dr. Bracha has global biotechnology experience, working at companies of various sizes and stages of development. Throughout her career, Dr. Bracha has been committed to advancing innovation and the development of novel therapies for patients.

“We’re thrilled to have Abigail on board, her deep corporate development experience will be crucial as we begin our journey toward the clinic and providing patients with important medicines,” stated Michal Golan Mashiach, Ph.D, founder and CEO of Edity.

Abigail Bracha joins from Clover Biopharmaceuticals where she served as Senior Vice President of Corporate Strategy and Business Development since 2021. Previously, Abigail held leadership positions at Rubius Therapeutics where she led corporate development. Earlier in her career, Abigail worked in corporate venture capital at GE Ventures and founded the global technology scouting team for GE Healthcare Life Sciences, where she built and led the Search and Evaluation team. She also worked in the technology sector at Amazon Web Services and Dell-EMC. Abigail completed her PhD from Harvard University in Experimental Pathology and was a National Science Foundation Graduate Research Fellow.

“I am excited to take this next step with Edity. I have seen the groundbreaking work and results of this talented team,” said Abigail Bracha, Edity’s new President. “This year stands to be a transformative year for Edity as we advance our pioneering oncology programs. I am eager to steer our strategic growth and financing initiatives.”

Edity’s proprietary delivery platform is a powerful tool for selective tissue targeting and protein delivery. In oncology, Edity is addressing the key challenges of cell therapies in solid tumors including, antigen heterogeneity, the immunosuppressive tumor microenvironment and tumor resistance to death.

To learn more about Edity, please visit

About Edity Therapeutics
Edity® Therapeutics has developed a proprietary platform for selective delivery of intracellular proteins to diseased tissues and is creating new cellular medicines with curative potential. Edity is pursuing multiple therapeutic areas and is the only company with the ability to target diseased cells with receptor-level specificity and unlock the intracellular proteome at scale. The company is developing multiple product candidates in oncology, gene therapy, autoimmunity, and regenerative medicine. Learn more at

( Press Release Image: )


 Cellular Reprogramming
 Immune System Reprogram
 Therapeutic Proteins
 Edity Therapeutics

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.